Virus Diseases

– Webcast to be Held at 8:00 am ET on November 7, 2024 – NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2024, including a corporate update, on Thursday, November 7, 2024, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET. To participate in the webcast, please register in advance at: or on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access. An archived replay of the webcast will be available approximately one hour after completion on Immunic's website at: ir.imux.com/events-and-presentations. About Immunic, Inc. Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, for which it is currently in preparations for a phase 2 clinical trial. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: . Cautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for Immunic's development programs to safely and effectively target diseases; preclinical and clinical data for Immunic's development programs; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company; and the company's expected cash runway. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, including the ability to satisfy the minimum average price and trading volume conditions required to receive funding in tranche 2 and 3 of the January 2024 private placement, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 22, 2024, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release. Contact Information Immunic, Inc. Jessica Breu Vice President Investor Relations and Communications +49 89 2080 477 09 [email protected] US IR Contact Rx Communications Group Paula Schwartz +1 917 633 7790 [email protected] US Media Contact KCSA Strategic Communications Caitlin Kasunich +1 212 896 1241 [email protected] SOURCE Immunic, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Kling-Select is a uniquely promising approach to identifying novel targets and therapeutic antibodies from human and animal sources Kling-Evolve enables highly rapid selection of effective neutralizing antibodies against viral escape variants AMSTERDAM, Oct. 31, 2024 /PRNewswire/ -- Kling Biotherapeutics ("Kling" or "the Company"), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announces that it will be presenting findings on its proprietary primary B-cell selection and evolution platform technologies, Kling-Select and Kling-Evolve at the Annual Protein & Antibody Engineering Summit (PEGS) Europe, held in Barcelona, Spain from 5-7 November 2024. Poster one entitled ' Highly efficient capture of circulating and tissue-infiltrating B cell repertoires from multiple species: Kling-Select,' describes advances in Kling-Select, a proprietary B-cell immortalization platform developed to efficiently capture and screen B cells demonstrating its promise as an approach to the identification of both valuable new targets and therapeutic antibodies. Kling-Select is applied for the immortalization of B cells derived from human and animal sources such as camelid, rabbit, mouse, and non-human primates. The poster also highlights advances in the optimization of the fully integrated workflow allowing the discovery of functional monoclonal antibodies from primary B cells in as little as three weeks. Poster two entitled ' Kling-Evolve as a tool for rapid response to emerging variants and pandemic preparedness: directed evolution of variant-specific antibody from immortalized B cells,' details the Kling-Evolve platform which enables the rapid ex vivo maturation of immortalized human B cells to identify neutralizing antibodies against escape variants. Kling-Evolve poses the potential for rapid development of countermeasures to combat and pre-emptively address evolving viruses amidst emerging pandemic threats. Michael Koslowski, Chief Executive Officer at Kling Biotherapeutics, said: "Our technology is a powerful platform which is clinically validated, having been used to discover the fully human Respiratory Syncytial Virus (RSV) neutralizing antibody nirsevimab (Beyfortus™ – AstraZeneca / Sanofi). By using an 'effective antibody first' discovery approach, Kling's platform technologies enable the discovery of relevant, completely novel antigen targets applicable to cancer as well as infectious diseases. Kling is well poised to develop next-generation antibody-based therapeutics to bring new, highly targeted treatments to cancer patients and address rising global concerns of the speed of response to emerging pandemic threats." Details of the poster presentations are as follows: Poster Title: Highly efficient capture of circulating and tissue-infiltrating B cell repertoires from multiple species: Kling-Select Presenter: Casper Marsman, Senior Scientist – B Cell Platform Lead, Kling Biotherapeutics Presentation Number: A073 Poster Title: Kling-Evolve as a tool for rapid response to emerging variants and pandemic preparedness: directed evolution of variant-specific antibody from immortalized B cells Presenter: Alessandra Villa, Director of Discovery Platforms, Kling Biotherapeutics Presentation Number: A074 Posters will be displayed in the Exhibit Hall at the following dates and times: Tuesday, 5 November from 10:30 – 19:35 CET Wednesday, 6 November from 10:30 -17:15 CET Thursday, 7 November from 10:00 – 13:55 CET About Kling Biotherapeutics Kling Biotherapeutics is a privately held biotech company focused on discovery and development of novel targets and therapeutics. The Company is headquartered in Amsterdam, the Netherlands with a fully owned IP portfolio that covers its proprietary platform technologies Kling-Select and Kling-Evolve for the simultaneous discovery of novel targets and identification of fully human antibodies directly from patient-derived B cells. Kling-Select relies on a fully-owned and clinically validated B cell immortalization and screening technology to identify novel therapeutic targets and antibody binders from patients with exceptional clinical responses. This technology has successfully identified novel neutralizing antibodies for various infectious diseases such as RSV (nirsevimab/Beyfortus), Covid, and Influenza. More recently, Kling-Select has been applied to peripheral and tumor-infiltrating B cells derived from cancer patients and produced a portfolio of novel and selective target-antibody pairs. The unbiased nature of this discovery platform allows identification of novel targets and unique epitopes inaccessible to traditional target discovery approaches. Kling-Evolve enables the ex vivo affinity maturation of B cell clones against targets of interest. This powerful technology can be used for the rapid evolution of neutralizing antibodies against emerging viral variants or for affinity and selectivity improvement of oncology assets. Kling Biotherapeutics is progressing a unique pipeline of oncology and infectious disease programs with KBA1412, a first-in-class CD9 antibody, being explored in blood cancers. About PEGS PEGS Europe is the largest protein & antibody engineering event in Europe which has been described as "the best biologics technology meeting in Europe." New this year, event has expanded to include coverage of AI/ML, Mult specific antibodies, antibody-drug conjugates, and an entire stream devoted to Oncology. SOURCE Kling Biotherapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

MUMBAI, India & HYDERABAD, India I October 30, 2024 I PopVax, an Indian full-stack biotechnology company developing novel mRNA vaccines and therapeutics using computational protein design, is pleased to announce that its ongoing research effort to develop lipid-polymer delivery formulations for thermostable mRNA vaccines has been funded by the Bill & Melinda Gates Foundation under a 1.15 million USD project agreement signed in October 2023. This effort follows on from a prior 2021 project agreement under which PopVax was awarded 100,000 USD to support the company’s earliest exploratory work on mRNA platform development and thermostable mRNA delivery formulations. These formulations are composed of novel lipids and polymers designed by PopVax. In September 2024, PopVax initiated the first animal study to determine the efficacy of a formulation from this project. The Principal Investigator for this project is Dr. Maunish Barvalia, PopVax’s Vice President of Platform Technologies, who previously worked with pioneering nucleic acid delivery research groups at NanoVation Therapeutics and during his PhD at the University of British Columbia in Canada. “We at PopVax are delighted to receive support to develop novel thermostable delivery formulations for mRNA-based vaccines and therapeutics, a critical challenge that is central to our public health mission. During the COVID-19 pandemic, mRNA vaccines were designed against the novel pathogen in three days, entered clinical trials less than two months from conception, and were able to scale to billions of manufactured doses in just one year. This speed, enabled by the flexibility of mRNA technology, was critical at a time when just days of delays meant potentially thousands of lives lost. The mRNA vaccines approved in the United States and Europe, however, required storage temperatures between -20 °C and -80 °C, which put them out of reach of developing countries without extensive supply chains that are able to maintain those below-freezing temperatures,” said Soham Sankaran, Founder & Managing Director of PopVax. “The delivery formulations we are developing as part of this project are intended to be stable at normal refrigerator temperatures while retaining their potency across a range of routes of administration. This will enable rapid, population-scale distribution of new mRNA vaccines and therapeutics to combat infectious disease in developing countries – both potential future pandemics and the deadly pathogens already among us.” PopVax ( https://popvax.com ) has developed a novel mRNA architecture for immunogen display on virus-like particles (VLPs), a lipid nanoparticle (LNP) delivery platform for mRNA using PopVax-designed novel ionizable lipids, and a machine learning-enabled computational approach to protein design. Together with the company’s GMP-ready infrastructure and process for clinical dose production, these platforms collectively form the foundation of PopVax’s ability to rapidly take new mRNA biomedicines from concept to clinic. Founded in late 2021, and previously incubated at the Centre for Cellular and Molecular Biology (CSIR-CCMB), PopVax now employs 70 people across its computational, experimental, analytical, process development, and quality teams at the RNA Foundry, its integrated R&D and process development facility in Hyderabad. PopVax’s first program is focused on the development of a broadly-protective next-generation COVID-19 vaccine covering both present and predicted future variants of SARS-CoV-2. This vaccine candidate is expected to enter human clinical trials in the United States of America in early 2025. PopVax has six novel vaccine candidates in its preclinical pipeline, and expects to initiate five clinical trials over the next two years. SOURCE: PopVax